← Leaderboards
Maria Cristina Gingerich
Cyanvac, Llc
$429,437
Attributed
$608,874
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $407K · FY2023–24$500K$375K$250K$125K$0
'23
'24
Funding mix
By agency
NIH$608,874 · 2
By mechanism
R21$358,875 · 1
R43$249,999 · 1
Top collaborators
- Jarrod Mousa2 shared
Others in their field
Other Rising Stars on “Glycoproteins”
- Robert W Cross · University Of Texas Med Br Galveston$4,640,498
- Kai Xu · Ohio State University$4,531,041
- Courtney Cohen · Albert Einstein College Of Medicine$3,541,248
- Torben Schiffner · Vanderbilt University$3,383,634
- Goran Bajic · Icahn School Of Medicine At Mount Sinai$3,116,277
- Choi-Fong Cho · Brigham And Women'S Hospital$2,666,597
Research focus
GlycoproteinsImmune ResponseElderlyGenomeGtp-Binding ProteinsHuman MetapneumovirusCytoplasmic TailDoseCombatGenesGrowthAntigensHospitalizationDelivery Vehicle10 Year OldBlood Group Antigen FBronchiolitisCanis FamiliarisAcute Respiratory InfectionCellsChildAntibodiesDistemperImmunization
Grant awards (3)
A parainfluenza virus 5 (PIV5)-based bivalent vaccine for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV)$201,900
R21 · FY2024 · AI · contact PI
Developing a PIV5-based human metapneumovirus (HMPV) vaccine$249,999
R43 · FY2023 · AI · contact PI
A parainfluenza virus 5 (PIV5)-based bivalent vaccine for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV)$156,975
R21 · FY2023 · AI · contact PI